期刊文献+

苄达赖氨酸离子敏感型眼用原位凝胶的研究 被引量:6

Prepration and Evaluation of Ion-sensitive Ophthalmic in Situ Gel Containing Bendazac Lysine
原文传递
导出
摘要 目的制备苄达赖氨酸离子敏感型眼用原位凝胶(BDZL-ISG),对其流变学特征、体外释放性和离体角膜渗透性等进行评价,并研究药物在兔眼房水初步的药动学特征。方法利用黏度和胶凝能力对处方进行单因素考察,筛选出最优处方;以市售滴眼液或溶液剂为对照,采用透析膜法考察该处方的体外释放性;采用Franz扩散池对该处方进行离体角膜渗透研究。并采用微透析取样技术初步研究了药物在兔眼房水中的药动学特征。结果该处方具有剪切稀释特性,相比于对照组缓释效果明显;离体角膜渗透研究结果表明,该处方角膜累积渗透率与市售处方无显著性差异。房水药动学结果表明,苄达赖氨酸离子敏感型眼用原位凝胶组给药后ρ_(max)(13.25μg·L^(-1))为市售组的2.38倍,AUC0-t为市售组的2.2倍,眼部生物利用度显著提高。结论苄达赖氨酸离子敏感型眼用原位凝胶缓释效果明显,能有效提高药物的眼部生物利用度,有望成为治疗白内障的新剂型。 OBJECTIVE To prepare ion-sensitive ophthalmic in situ gel containing bendazac lysine(BDZL-ISG) and preliminarily study its rheological behavior,in vitro drug release,corneal permeation,and pharmacokinetics in rabbit aqueous humor.METHODS Single factor investigation was carried out to optimize the formulation,taking viscosity and gelling capacity as evaluation indices.Using aqueous solution or eye drops as control,the in vitro release of the formulation was evaluated by dialysis membrane method.Then,the corneal permeation experiment of the optimum formulation was carried out with Franz diffusion cell.The pharmacokinetics of BDZL-ISG in rabbit aqueous humor was preliminarily studied by microdialysis.RESULTS Compared with the control group,the optimum formulation had shear thinning behavior and significant sustained release effect.There was no significant difference in the corneal permeation between the two groups.The results of pharmacokinetic study showed that ρmax(13.25 μg·L^(-1)) and AUC0-tof BZDL-ISG were 2.38 and 2.2 times higher than those of BDZL eye drops respectively,which suggested that the ocular bioavailability of BDZL was greatly enhanced by the optimum in situ gel formulation.CONCLUSION With significant sustained release effect,the ion-sensitive ophthalmic in situ gel will become a promising alterative formulation for bendazac lysine for treatment of cataracts.
出处 《中国药学杂志》 CAS CSCD 北大核心 2016年第12期999-1005,共7页 Chinese Pharmaceutical Journal
基金 浙江省医学重点学科群资助项目(XKQ-010-001) 浙江省医科院青年基金资助项目(2013Y002) 浙江省医药卫生科技资助项目(2014KYB068)
关键词 原位凝胶 苄达赖氨酸 释放 渗透 药动学 in situ gel ocular bendazac lysine release permeation pharmacokinetics
  • 相关文献

参考文献16

  • 1BALFOUR J A, CLISSOLD S P. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts [J]. Drugs, 1990, 39 (4):575-596.
  • 2ALMEIDA H, AMARAL M H, LOBAO P, et al. In situ gelling systems:a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations [J]. Drug Discov Today, 2014, 19 (4):400-412.
  • 3GEETHALAKSHMI A, KARKI R, JHA S K, et al. Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system [J]. Curr Drug Deliv, 2012, 9 (2):197-204.
  • 4李馨儒,雷耀龙,沈传勇,周艳霞,陈星伟,刘艳.阿昔洛韦眼用pH敏感原位凝胶剂的制备和评价[J].中国新药杂志,2009,18(24):2360-2364. 被引量:12
  • 5谢悦良,范景辉,丁劲松,裴奇,张毕奎.川陈皮素温敏型鼻用原位凝胶体外释药行为研究[J].中国医药工业杂志,2011,42(3):189-192. 被引量:9
  • 6EL-LAITHY H M, NESSEEM D I, EL-ADLY A A, et al. Moxifloxacin-Gelrite in situ ophthalmic gelling system against photodynamic therapy for treatment of bacterial corneal inflammation [J]. Arch Pharm Res, 2011, 34 (10):1663-1678.
  • 7LIU Y, LIU J, ZHANG X, et al. In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery [J]. AAPS Pharm Sci Tech, 2010, 11 (2):610-620.
  • 8LU B. New Techniques and New Dosage Forms of Drug(药物新剂型与新技术)[M]. 2nd ed. Beijing:People's Medical Publishing House,2005. 386-387.
  • 9SRIVIDYA B, CARDOZA R M, AMIN P D. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system [J]. J Controlled Release, 2001, 73 (2-3):205-211.
  • 10QIAN S, WONG Y C, ZUO Z. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine [J]. Int J Pharm, 2014, 468 (1-2):272-282.

二级参考文献30

  • 1孟岳成,洪伦波,陈波,王伟潮.结冷胶的成胶特性及应用研究进展[J].中国食品添加剂,2006,17(C00):63-66. 被引量:7
  • 2WHITLEY RJ. Herpes simplex virus infection [J]. Semin pediatr Infect Dis,2002,13( 1 ) :6 - 11.
  • 3STEPHEN R,CHU HT. Effect of aeyclovir on herpetic ocular recurrence using a structural nested model[ J ]. Contemporary Clinical Trials,2005,26 ( 3 ) : 300 - 310.
  • 4VANDAMME THF, BROBECKL. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of piloearpine nitrate and tropicamide [ J ]. J Control Release,2005,102 ( 1 ) :23 - 38.
  • 5GIUNCHEDI P,CONTE U ,CHETONI P,et al. Pectin microspheres as ophthahnic carries for piroxicam:evaluation in vitro and in vivo albino rabbits [J]. Euro J Pharm Scl, 1999,9( 1 ) : 1- 7.
  • 6EDSM AN K, CARLFORS J, HARJU K, et al. Rheological evaluation and ocular contact lime of some carbomer gels for ophthalmic use [J]. Inter J Pharm,1996,137(2) :233 -241.
  • 7国家药品食品监督管理局,化学药物刺激性、过敏性和溶血性研究技术指导原则[S],2005,[H]GPT4-1.
  • 8MAJUMDAR S, HIPPALGAONKAR K ,REPKA MA. Effect of chitosan,benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyelovir across isolated rabbit cornea [ J]. Inter J Pharm,2008,348(1- 2) :175 - 178.
  • 9KUMAR SR, HIMMESTEIN KJ. Modification of in situ gelling behavior of carbopol solutions by hydroxypropylmethylcellulose [ J ]. J Pharm Sci, 1995,84 ( 3 ) : 344 - 348.
  • 10HOTHNER H, WAAI,ER T, WIK O. Rheological characterization of tear substitutes [J].Drug Dev lnd Pharm, 1990,16 ( 1 ) :755 - 768.

共引文献36

同被引文献58

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部